Development
Sarepta Therapeutics, Inc.
SRPT
$16.75
-$0.35-2.05%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 53.54% | 44.10% | 11.89% | 20.24% | 28.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.54% | 44.10% | 11.89% | 20.24% | 28.28% |
| Cost of Revenue | -2.01% | -9.87% | -4.86% | 24.37% | 7.03% |
| Gross Profit | 1,036.34% | 480.79% | 73.91% | -82.98% | 151.05% |
| SG&A Expenses | 9.31% | 15.37% | -23.17% | 54.11% | 54.35% |
| Depreciation & Amortization | 326.26% | 146.63% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.89% | -2.48% | -11.21% | 31.53% | 19.06% |
| Operating Income | 123.05% | 84.13% | 36.76% | -58.94% | -1.44% |
| Income Before Tax | 139.85% | 87.06% | 93.61% | -392.30% | 16.89% |
| Income Tax Expenses | -166.57% | 488.11% | 176.12% | 360.18% | 8,528.26% |
| Earnings from Continuing Operations | 141.79% | 84.12% | 89.66% | -392.03% | 10.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 141.79% | 84.12% | 89.66% | -392.03% | 10.44% |
| EBIT | 123.05% | 84.13% | 36.76% | -58.94% | -1.44% |
| EBITDA | 137.39% | 91.78% | 39.02% | -66.46% | -1.05% |
| EPS Basic | 139.21% | 84.34% | 89.80% | -386.82% | 12.37% |
| Normalized Basic EPS | 126.46% | 88.37% | 44.39% | -28.61% | 20.73% |
| EPS Diluted | 134.54% | 84.34% | 89.81% | -386.83% | 12.40% |
| Normalized Diluted EPS | 123.47% | 88.37% | 44.39% | -28.61% | 20.73% |
| Average Basic Shares Outstanding | 6.58% | 1.44% | 1.41% | 1.07% | 2.20% |
| Average Diluted Shares Outstanding | 20.21% | 1.44% | 1.41% | 1.07% | 2.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |